- Earnings per share of $0.85, beating the estimated $0.79.
- Reported revenue of approximately $2.93 billion, significantly exceeding the estimated $1.51 billion.
- Announced a $500 million share buyback plan and a 14% increase in share price post-earnings announcement.
Smith & Nephew PLC (NYSE:SNN), a global medical technology company specializing in advanced wound management, orthopedics, and sports medicine, competes with other major players in the medical technology sector, such as Johnson & Johnson and Medtronic. SNN’s recent financial performance has been noteworthy, with significant growth in revenue and earnings.
On August 5, 2025, SNN reported earnings per share of $0.85, surpassing the estimated $0.79. The company also reported revenue of approximately $2.93 billion, significantly exceeding the estimated $1.51 billion. This strong performance was highlighted during their Q2 2025 earnings conference call, led by CEO Deepak S. Nath and CFO John Terence Rogers, with participation from analysts from major financial institutions.
Following the announcement, SNN’s share price increased by 14%, reflecting investor confidence in the company’s growth trajectory. The company also announced a $500 million share buyback plan for the second half of the year, underscoring its strong cash generation and healthy balance sheet. The Advanced Wound Management division played a crucial role, contributing to a 4.7% increase in first-half revenue, totaling $2.96 billion.
Operating profit for SNN rose by 30.6% to $429 million, with the operating margin expanding to 14.5%. Trading profit increased by 11.2% to $523 million, achieving a margin of 17.7%. The company reported a strong cash flow, with cash from operations up by 54.3% to $568 million and free cash flow rising to $244 million from $39 million the previous year. Earnings per share grew by 36.6% to 33.5 cents, and the interim dividend was increased by 4.2% to 15 cents per share.
SNN’s financial metrics indicate a solid position in the market. The company’s price-to-earnings (P/E) ratio is approximately 37.30, while the price-to-sales ratio stands at about 2.65. The enterprise value to sales ratio is around 3.12, and the enterprise value to operating cash flow ratio is approximately 18.34. The debt-to-equity ratio is 0.63, and the current ratio is approximately 2.89, suggesting a strong ability to cover short-term liabilities.
